Sponsor: Eikon Therapeutics
Sponsor Study ID: EIK1003-001 (IMP1734-101)
Study Title: A First-in-Human, Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose-Optimization, and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PARP1 Selective Inhibitor, IMP1734, in Patients with Advanced Solid Tumors
CTO #: 103989
NCT Number: NCT06253130
Phase: I/II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Ovary, Prostate, Breast
Study Objectives: To evaluate the safety and tolerability of IMP1734. To determine the MTD (or MAD) and RDE. To characterize the plasma PK profile of single and multiple doses of IMP1734. To assess preliminary anti-tumor activity of IMP1734.